CPI Logo-Color.png
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
June 12, 2020 02:30 ET | Constellation Pharmaceuticals , Inc.
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
March 10, 2020 16:12 ET | Constellation Pharmaceuticals , Inc.
Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to...
CPI Logo-Color.png
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results
March 06, 2020 13:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
CPI Logo-Color.png
Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
December 10, 2018 16:49 ET | Constellation Pharmaceuticals , Inc.
Dosing has begun in a randomized study of CPI-1205 / enzalutamide combination versus enzalutamide alone in second-line mCRPCSingle-arm CPI-1205 / abiraterone / prednisone combination added to...